GOUT: FROM HYPERURICEMIA A CHRONIC INFLAMMATORY ARTHRITIS

Yogesh Thakur, Dr. Sunita Dhiman*, Dr. Jyoti Gupta, Dr. Nisha Devi

ABSTRACT

Gout is a long-standing, progressive inflammatory joint disorder caused by the accumulation of monosodium urate crystals within joints and surrounding tissues due to persistent hyperuricemia. It is among the most common forms of inflammatory arthritis globally, and its prevalence continues to increase as a result of longer life expectancy, altered dietary habits, rising obesity rates, metabolic syndrome, chronic renal impairment, and extensive use of diuretic medications. The underlying pathophysiology of gout is multifactorial, involving abnormalities in uric acid metabolism, crystal deposition, and activation of the innate immune response, particularly through stimulation of the NLRP3 inflammasome, leading to the release of pro-inflammatory mediators such as interleukin-1β. From a clinical perspective, gout typically manifests as recurrent episodes of acute, intense joint pain accompanied by swelling, redness, and tenderness, most frequently involving the first metatarsophalangeal joint. If inadequately managed, the disease may advance to chronic tophaceous gout, resulting in joint damage, deformity, and functional disability. Definitive diagnosis is classically achieved by the detection of monosodium urate crystals in synovial fluid; however, recent advances in imaging techniques, including musculoskeletal ultrasound and dual-energy computed tomography, have significantly improved diagnostic precision, particularly in early or atypical presentations. Therapeutic management of gout includes both the control of acute inflammatory flares and long-term reduction of serum urate levels. Acute episodes are commonly treated with nonsteroidal anti-inflammatory drugs, colchicine, or corticosteroids, whereas long-term management aims to achieve and maintain target urate concentrations using xanthine oxidase inhibitors, uricosuric agents, or novel biologic therapies in resistant cases. Contemporary clinical guidelines support a treat-to-target strategy and highlight the importance of patient education, lifestyle interventions, and effective management of comorbid conditions. Nonetheless, despite the availability of effective therapies, gout remains underrecognized and insufficiently controlled, emphasizing the need for greater awareness, guideline-based care, and a multidisciplinary approach to minimize disease burden and long-term complications.

Keywords: Gout; Hyperuricemia; Monosodium urate crystals; Inflammatory arthritis; NLRP3 inflammasome; Interleukin-1?; Acute gout flare.